R&D channel feed – Endpoints News

R&D channel feed

Allergan CEO Brent Saunders takes a pricing pledge: Predatory practices must end

9 years ago

After landing a $354M payout, Medivation CEO David Hung doesn’t overlook his 2016 bonus

9 years ago

Karyopharm sets a course for the FDA with positive PhIIb multiple myeloma data

9 years ago

AstraZeneca offers some mixed PhIII results for severe asthma, while Roche rival flounders

9 years ago

Novartis’ CAR-T chief Azam is leaving, but pharma giant denies any ‘retreat’ is underway

9 years ago

Stroke risk forces Merck to scrap its long-neglected PhIII osteoporosis drug odanacatib

9 years ago

Scoop: Novartis’ retreat on CAR-T includes axing most of its senior execs on the team

9 years ago

Momenta’s failed pancreatic cancer drug is given a midnight funeral

9 years ago

Who’s been dipping their fingers into the till at Parexel?

9 years ago

Roche racks up another checkpoint win as Tecentriq scores in latest PhIII lung cancer study

9 years ago

Sunovion bags PhIII Parkinson’s drug in $624M Cynapsus buyout

9 years ago

Biogen hypes a fresh set of early, upbeat results for Alzheimer’s drug

9 years ago

Scoop: Novartis disbands its pioneering cell and gene therapy unit

9 years ago

Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D into a separate company

9 years ago

Abandoned in PhIII, Onconova sacrifices more staffers to its survival strategy

9 years ago

FDA hands Novartis the keys to a $5B Amgen franchise

9 years ago

Protocols: CRO industry poised for steady growth as new work in China explodes (in a good way); Vectura dinged on PhIII Flutiform flop

9 years ago

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

9 years ago

As cardio R&D shrinks in size, a new study highlights some serious pitfalls – and a positive shift

9 years ago

AMRI plans to ax staffers, restructure after completing a $358M buyout

9 years ago

Rigel's positive PhIII for bleeding disorder triggers a roller coaster ride for shares

9 years ago

Struggling CTI gets a mixed bag of PhIII results for a lead drug still under a full hold at the FDA

9 years ago

A scientist wages a war over women’s 'second-rate' status at the NIH

9 years ago

Booming Moderna is raising $600M while ramping up manufacturing and clinical studies

9 years ago

First page Previous page 320 321 322323324 325 326 Next page Last page